Medical Cannabis Studies

• View All (505)

Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function (2012)

CBD has been shown to have short-term neuroprotective effects in the immature brain, suggesting that it could be used as a neuroprotective agent for neonatal hypoxiaeischemia. View study
Cannabidiol and (?)?9-tetrahydrocannabinol are neuroprotective antioxidants (1998)

These data suggest that the non-psychotropic cannabinoid of natural origin CBD has therapeutic potential for the treatment of neurological oxidative disorders such as cerebral ischemia. View study
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease (2011)

Based on the results of this study it was found that cannabidiol (CBD) has the ability to modulate the function of the microglial cell in vitro, inducing beneficial effects in an in vivo model of Alzheimer’s disease, thus indicating that CBD has the potential to represent a new therapeutic approach to treat this disease. View study
Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice (2008)

The results of the studies carried out on non-obese female mice with a tendency to diabetes (NOD), show that when cannabidiol (CBD) is administered by presenting the mice with a latent or initial state of diabetes, the mice reflect improvement of the disease. This reinforces the assumption that CBD, could be used in humans, for the treatment of type 1 diabetes. View study
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells (2007)

CBD would help treat breast cancer since it can significantly decrease the development of metastatic cells. View study
Cannabidiol as a potential treatment for psychosis (2013)

A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study
Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. (2019)

Epilepsy is one of the most common chronic brain disorders that affects around 70 million people worldwide. The objective of this article was to make a critical review of the pharmacology of Cannabidiol (CBD) and the most recent clinical studies who evaluated its efficacy and safety as a complementary treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). View study
Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress (2011)

This review discusses recent research that states that CBD can contribute to the treatment of diseases and disorders such as rheumatoid arthritis, type I and II diabetes, atherosclerosis and Alzheimer’s disease. View study
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence (2015)

Some preclinical studies say that cannabidiol (CBD) can have therapeutic properties on opiates, cocaine and psychostimulant addiction. They also suggest that CBD may be beneficial for the consumption of cannabis and tobacco in humans. However, more studies are needed to fully verify the potential of the CBD. View study
Cannabidiol as potential anticancer drug (2012)

There is emerging evidence to suggest that cannabidiol (CBD) is a potent inhibitor of cancer growth and spread. Its effectiveness is linked to its ability to target multiple cellular pathways that control tumorigenesis through the modulation of different intracellular signals depending on the type of cancer considered. View study
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (2010)

These results indicate that the CBD could have an enormous therapeutic potential to treat diabetic and cardiovascular complications due to its ability to reduce inflammation, oxidative stress, nitration, fibrosis and cell death. View study
Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. (2018)

The toxicity studies of Cannabidiol (CBD) are of great importance to ensure the safety of patients. In this context, the morphological analysis of the zebrafish can contribute to evaluate the teratogenic potential, as well as the evaluation of the acetylcholinesterase activity and the motor activity of the zebrafish are valuable tools to verify the potential of neurotoxicity. The results suggest that the effects observed after exposure to CBD are closely related to the CB1 receptor that is present in the zebrafish from the earliest stages of development. View study